The management of Clostridium difficile infection: Antibiotics, probiotics and other strategies

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 5-13

  Senok, A C ^a   Rotimi, Vincent O ^b  

^a UNIVERSITY OF SHARJAH   (United Arab Emirates)

^b MUBARAK AL KABEER HOSPITAL   (Kuwait)

Author keywords

Clostridium difficile; Colitis; Diarrhea; Ion exchange resins; Probiotics

Indexed keywords

ADSORBENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACITRACIN; BACTERIAL VACCINE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE VACCINE; COLESTIPOL; COLESTYRAMINE; ENEMA; FUSIDIC ACID; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; ION EXCHANGE RESIN; MACROGOL; METRONIDAZOLE; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAXIMIN; SYNSORB 90; TEICOPLANIN; TOLEVAMER; UNCLASSIFIED DRUG; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM ADHERENCE; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE INTAKE; ENZYME IMMUNOASSAY; FOLLOW UP; FUNGEMIA; HOSPITALIZATION; HUMAN; HYPOKALEMIA; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION RISK; META ANALYSIS; MONOTHERAPY; NONHUMAN; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TOXIC MEGACOLON; TOXIN ANALYSIS; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VIRULENCE; WHEY;

EID: 41149105986     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.1.5     Document Type: Review

References (112)

1. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5: 549-557.
2. Bartlett JG. Clostridium difficile: clinical considerations. Rev Infect Dis 1990; 12 (Suppl 2): S243-S251.
3. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-372.
4. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12: 409-415.
5. Morris AM, Jobe BA, Stoney M, Sheppard BC, Deveney CW, Deveney KE. Clostridium difficile colitis: an increasingly aggressive iatrogenic disease? Arch Surg 2002; 137: 1096-1100.
6. Barbut F, Delmee M, Brazier JS, Petit JC, Poxton IR, Rupnik M et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Microbiol Infect 2003; 9: 989-996.
7. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145: 758-764.
8. Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 2007; 44: 238-244.
9. McDonald LC, Killgore GE, Thompson A, Owens RC, Jr., Kazakova SV, Sambol SP et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-2441.
10. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-1260.
11. Bouza E, Munoz P, Alonso R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 2005; 11 (Suppl 4): 57-64.
12. Johnson S, Samore MH, Farrow KA, Killgore GE, Tenover FC, Lyras D et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999; 341: 1645-1651.
13. Lusk RH, Fekety R, Silva J, Browne RA, Ringler DH, Abrams GD. Clindamycin-induced enterocolitis in hamsters. J Infect Dis 1978; 137: 464-475.
14. de Lalla F, Privitera G, Ortisi G, Rizzardini G, Santoro D, Pagano A, et al. Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital. J Antimicrob Chemother 1989; 23: 623-631
15. Thomas C, Stevenson M, Williamson DJ, Riley TV. Clostridium difficile-associated diarrhea: epidemiology data from Western Australia associated with a modified antibiotic policy. Clin Infect Dis 2002; 35; 1457-1462.
16. Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA. Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidermiol 2005; 26: 680-684.
17. Kazakova SV, Ware K, Baughman B, Bilukha O, Paradis A, Sears S et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006; 166: 2518-2524.
18. McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003; 9: 730-733.
19. Rotimi VO, Mokaddas EM, Jamal WY, Verghese TL, el-Din K, Junaid TA. Hospital-acquired Clostridium difficile infection amongst ICU and burn patients in Kuwait. Med Princ Pract 2002; 11: 23-28.
20. Bender BS, Bennett R, Laughon BE, Greenough WB, III, Gaydos C, Sears SD et al. Is Clostridium difficile endemic in chronic-care facilities? Lancet 1986; 2: 11-13.
21. Brazier JS, Fitzgerald TC, Hosein I, Cefai C, Looker N, Walker M et al. Screening for carriage and nosocomial acquisition of Clostridium difficile by culture: a study of 284 admissions of elderly patients to six general hospitals in Wales. J Hosp Infect 1999; 43: 317-319.
22. McCoubrey J, Starr J, Martin H, Poxton IR. Clostridium difficile in a geriatric unit: a prospective epidemiological study employing a novel S-layer typing method. J Med Microbiol 2003; 52: 573-578.
23. Starr J. Clostridium difficile associated diarrhoea: diagnosis and treatment. BMJ 2005; 331: 498-501.
24. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320: 204-210.
25. Rotimi VO, Jamal WY, Mokaddas EM, Brazier JS, Johny M, Duerden BI. Prevalent PCR ribotypes of clinical and environmental strains of Clostridium difficile isolated from intensive-therapy unit patients in Kuwait. J Med Microbiol 2003; 52: 705-709.
26. Brown E, Talbot GH, Axelrod P, Provencher M, Hoegg C. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 1990; 11: 283-290.
27. Schroeder MS. Clostridium difficile - associated diarrhea. Am Fam Physician 2005; 71: 921-928.
28. Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE. Past, present, and future therapies for Clostridium difficile-associated disease. Ann Pharmacother 2006; 40: 2155-2163.
29. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006; 24: 613-619.
30. Samore MH, Bettin KM, DeGirolami PC, Clabots CR, Gerding DN, Karchmer AW. Wide diversity of Clostridium difficile types at a tertiary referral hospital. J Infect Dis 1994; 170: 615-621.
31. McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005; 40: 265-272.
32. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-1084.
33. Poxton IR, McCoubrey J, Blair G. The pathogenicity of Clostridium difficile. Clin Microbiol Infect 2001; 7: 421-427.
34. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-262.
35. Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immunol 2003; 71: 1608-1610.
36. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390-397.
37. Mulligan ME, Miller SD, McFarland LV, Fung HC, Kwok RY. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 1993; 16 (Suppl 4): S239-S244.
38. Lozniewski A, Rabaud C, Dotto E, Weber M, Mory F. Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of Premier Cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains. J Clin Microbiol 2001; 39: 1996-1998.
39. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-1775.
40. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38: 2386-2388.
41. Johnson S, Adelmann A, Clabots CR, Peterson LR, Gerding DN. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 1989; 159: 340-343.
42. Tang-Feldman Y, Mayo S, Silva JJ, Jr., Cohen SH. Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent Clostridium difficile-associated diarrhea. J Clin Microbiol 2003; 41: 3413-3414.
43. Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984; 6 (Suppl 1): S235-S241.
44. Olson MM, Shanholtzer CJ, Lee JT, Jr., Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994; 15: 371-381.
45. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2: 1043-1046.
46. Khan MY, Hall WH. Staphylococcal enterocolitis - treatment with oral vancomycin. Ann Intern Med 1966; 65: 1-8.
47. Wallace JF, Smith RH, Petersdorf RG. Oral administration of vancomycin in the treatment of staphylococcal enterocolitis. N Engl J Med 1965; 272: 1014-1015.
48. Gerding DN. Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis 2005; 40: 1598-1600.
49. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mort Wkly Rep 1995; 44: 1-13.
50. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995; 23: 87-94.
51. Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2005; (1): CD004610.
52. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813-818.
53. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 1586-1590.
54. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-1597.
55. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 2004; 38: 414-418.
56. Modena S, Gollamudi S, Friedenberg F. Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2006; 40: 49-54.
57. Jamal WY, Mokaddas EM, Verghese TL, Rotimi VO. In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait. Int J Antimicrob Agents 2002; 20: 270-274.
58. Friedenberg F, Fernandez A, Kaul V, Niami P, Levine GM. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001; 44: 1176-1180.
59. Nathanson DR, Sheahan M, Chao L, Wallack MK. Intracolonic use of vancomycin for treatment of Clostridium difficile colitis in a patient with a diverted colon: report of a case. Dis Colon Rectum 2001; 44: 1871-1872.
60. Gerding DN. Treatment of Clostridium difficile-associated diarrhea and colitis. Curr Top Microbiol Immunol 2000; 250: 127-139.
61. Tonna I, Welsby PD. Pathogenesis and treatment of Clostridium difficile infection. Postgrad Med J 2005; 81: 367-369.
62. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80: 867-868.
63. de LF, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992; 36: 2192-2196.
64. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med 1986; 146: 1101-1104.
65. Young GP, Ward PB, Bayley N, Gordon D, Higgins G, Trapani JA et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985; 89: 1038-1045.
66. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report: Cordoba, Argentina 2001; 1-34.
67. Senok AC, Ismaeel AY, Botta GA. Probiotics: facts and myths. Clin Microbiol Infect 2005; 11: 958-966.
68. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324: 1361.
69. Szajewska H, Ruszczynski M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr 2006; 149: 367-372.
70. Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ 2006; 175: 377-383.
71. Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996; 64: 5225-5232.
72. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67: 302-307.
73. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005; 21: 583-590.
74. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31: 1012-1017.
75. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812-822.
76. Niault M, Thomas F, Prost J, Ansari FH, Kalfon P. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin Infect Dis 1999; 28: 930.
77. Schlegel L, Lemerle S, Geslin P. Lactobacillus species as opportunistic pathogens in immunocompromised patients. Eur J Clin Microbiol Infect Dis 1998; 17: 887-888.
78. Furrie E, Senok AC, Frank DN, Sullivan KE. Pondering probiotics. Clin Immunol 2006; 121: 19-22.
79. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 2005; 3: 442-448.
80. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36:580-585.
81. Schwan A, Sjolin S, Trottestam U, Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet 1983; 2: 845.
82. Schwan A, Sjolin S, Trottestam U, Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 1984; 16: 211-215.
83. Liacouras CA, Piccoli DA. Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis. J Clin Gastroenterol 1996; 22: 186-189.
84. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118: 633-637.
85. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006; 49: 640-645.
86. Murphy C, Vernon M, Cullen M. Intravenous immunoglobulin for resistant Clostridium difficile infection. Age Ageing 2006; 35: 85-86.
87. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004; 53: 882-884.
88. van Dissel JT, de GN, Hensgens CM, Numan S, Kuijper EJ, Veldkamp P et al. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 2005; 54: 197-205.
89. Young KW, Munro IC, Taylor SL, Veldkamp P, van Dissel JT. The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile. Regul Toxicol Pharmacol 2007; 47: 317-326
90. Ariano RE, Zhanel GG, Harding GK. The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis. CMAJ 1990; 142: 1049-1051.
91. Barker RH, Jr., Dagher R, Davidson DM, Marquis JK. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharmacol Ther 2006; 24: 1525-1534.
92. Kunimoto D, Thomson AB. Recurrent Clostridium difficile-associated colitis responding to cholestyramine. Digestion 1986; 33: 225-228.
93. Moncino MD, Falletta JM. Multiple relapses of Clostridium difficile-associated diarrhea in a cancer patient. Successful control with long-term cholestyramine therapy. Am J Pediatr Hematol Oncol 1992; 14: 361-364.
94. Pruksananonda P, Powell KR. Multiple relapses of Clostridium difficile-associated diarrhea responding to an extended course of cholestyramine. Pediatr Infect Dis J 1989; 8: 175-178.
95. Mogg GA, George RH, Youngs D, Johnson M, Thompson H, Burdon DW et al. Randomized controlled trial of colestipol in antibiotic-associated colitis. Br J Surg 1982; 69: 137-139.
96. Pantosti A, Luzzi I, Cardines R, Gianfrilli P. Comparison of the in vitro activities of teicoplanin and vancomycin against Clostridium difficile and their interactions with cholestyramine. Antimicrob Agents Chemother 1985; 28: 847-848.
97. Taylor NS, Bartlett JG. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 1980; 141: 92-97.
98. Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43: 411-420.
99. Nilsson UJ, Heerze LD, Liu YC, Armstrong GD, Palcic MM, Hindsgaul O. Immobilization of reducing sugars as toxin binding agents. Bioconjug Chem 1997; 8: 466-471.
100. Castagliuolo I, LaMont JT, Qiu B, Nikulasson ST, Pothoulakis C. A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileum. Gastroenterology 1996; 111: 433-438.
101. Heerze LD, Kelm MA, Talbot JA, Armstrong GD. Oligosaccharide sequences attached to an inert support (SYN-SORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis. J Infect Dis 1994; 169: 1291-1296.
102. Broekhuysen J, Stockis A, Lins RL, De GJ, Rossignol JF. Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 2000; 38: 387-394.
103. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000; 44: 2254-2258.
104. Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006; 43: 421-427.
105. Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007; doi:10.1093/jac/dkl553.
106. VA Medical Center HBCoM. Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection. http://clinicaltrials.gov/ ct/show/NCT00304356 (Last accessed March 19 2007).
107. VA Medical Center HBCoM. Vancomycin Vs. Nitazoxanide to Treat Clostridium Difficile Colitis That Has Failed Therapy With Metronidazole. http://clinicaltrials.gov/ct/show/NCT00304889 (Last accessed March 19 2007).
108. Anton PM, O'Brien M, Kokkotou E, Eisenstein B, Michaelis A, Rothstein D et al. Rifalazil treats and prevents relapse of Clostridium difficile-associated diarrhea in hamsters. Antimicrob Agents Chemother 2004; 48: 3975-3979.
109. Kotloff KL, Wasserman SS, Losonsky GA, Thomas W, Jr., Nichols R, Edelman R et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001; 69: 988-995.
110. Ozawa TT, Valadez T. Clostridium difficile infection associated with levofloxacin. Tenn Med 2002; 95: 113-115
111. Price MF, Dao-Tran T, Garey KW, Graham G, Gentry LO, Dhungana L, et al. Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. J Hosp Infect 2007; 65: 42-26.
112. Bloomfield SF, Cookson B, Falkiner F, Griffith C, Cleary V. Methicillin-resistant Staphylococcus aureus, Clostridium difficile, and extended-spectrum beta-lactamase-producing Escherichia coli in the community: assessing the problem and controlling the spread. Am J Infect Control 2007; 35: 86-88